Drug details

Ziextenzo (pegfilgrastim-bmez injection)

type of Hematopoietic Growth Factors

Ziextenzo (pegfilgrastim-bmez) is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non¬myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. Ziextenzo is biosimilar to Neulasta (pegfilgrastim).

This drug may have the following side effects:

• hives,
• difficulty breathing,
• swelling of your face, lips, tongue, or throat,
• fever,
• skin rash,
• easy bruising,
• unusual bleeding,
• pale skin,
• lightheadedness,
• shortness of breath,
• fast heartbeats,
• rapid breathing,
• tiredness,
• dizziness,
• swelling,
• wheezing,
• sweating,
• little or no urination,
• decreased urination,
• bruising,
• sudden swelling,
• feeling of fullness,
• sudden or severe pain in your left upper stomach spreading up to your shoulder,
• warmth or tingly feeling,
• puffiness,
• sudden and severe pain in your chest, stomach, or back,
• severe or ongoing pain anywhere in your body,
• pink or dark urine, and
• swelling in your face or lower legs
• hard lump where the medicine was injected,

The following drugs are related to Ziextenzo, either as a replacement or used together:

• Zarxio (filgrastim-sndz injection)
• Fulphila (pegfilgrastim-jmdb injection, for subcutaneous use)
• Neulasta (pegfilgrastim)
• Nyvepria (pegfilgrastim-apgf injection)
• Udenyca (pegfilgrastim-cbqv injection)
• Stimufend (pegfilgrastim-fpgk)
• Yondelis (trabectedin for injection)